Danazol is under clinical development by Viramal and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Danazol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Danazol is under development for the treatment of endometriosis. The drug candidate is formulated as a locally targeted vaginal cream. It acts by targeting androgen receptor, progesterone receptor and estrogen receptor.
Viramal is a pharmaceutical and health care company that provides women’s health products. The company offers discovery and development of therapeutics to improve women’s health. Its products portfolio includes elegant vaginal moisturizer that is used for the treatment of vaginal atrophy and prevention of local infections through pH modification; and testocream and estrogen therapy, among others. Viramal’s products are used in the treatment of menopausal hormone therapy, fertility, contraception and sexual health. The company also provides prescription drugs and non-prescription drugs. It has its operations in the UK and the US. Viramal is headquartered in London, England, the UK.
For a complete picture of Danazol’s drug-specific PTSR and LoA scores, buy the report here.